Insights into the Cellular Interactions and Molecular Mechanisms of Ketogenic Diet for Comprehensive Management of Epilepsy

A high-fat diet with appropriate protein and low carbohydrate content, widely known as the ketogenic diet (KD), is considered as an effective non-pharmacotherapeutic treatment option for certain types of epilepsies. Several preclinical and clinical studies have been carried out to elucidate its mech...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current neuropharmacology 2022-01, Vol.20 (11), p.2034-2049
Hauptverfasser: Kumar, Amit, Kumari, Savita, Singh, Damanpreet
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2049
container_issue 11
container_start_page 2034
container_title Current neuropharmacology
container_volume 20
creator Kumar, Amit
Kumari, Savita
Singh, Damanpreet
description A high-fat diet with appropriate protein and low carbohydrate content, widely known as the ketogenic diet (KD), is considered as an effective non-pharmacotherapeutic treatment option for certain types of epilepsies. Several preclinical and clinical studies have been carried out to elucidate its mechanism of antiepileptic action. Ketone bodies produced after KD's breakdown interact with cellular excito-inhibitory processes and inhibit abnormal neuronal firing. The generated ketone bodies decrease glutamate release by inhibiting the vesicular glutamate transporter 1 and alter the transmembrane potential by hyperpolarization. Apart from their effect on the well-known pathogenic mechanisms of epilepsy, some recent studies have shown the interaction of KD metabolites with novel neuronal targets, particularly adenosine receptors, adenosine triphosphate-sensitive potassium channel, mammalian target of rapamycin, histone deacetylase, hydroxycarboxylic acid receptors, and the NLR family pyrin domain containing 3 inflammasomes to suppress seizures. The role of KD in augmenting gut microbiota as a potential mechanism for epileptic seizure suppression has been established. Furthermore, some recent findings also support the beneficial effect of KD against epilepsy- associated comorbidities. Despite several advantages of the KD in epilepsy management, its use is also associated with a wide range of side effects. Hypoglycemia, excessive ketosis, acidosis, renal stones, cardiomyopathies, and other metabolic disturbances are the primary adverse effects observed with the use of KD. However, in some recent studies, modified KD has been tested with lesser side effects and better tolerability. The present review discusses the molecular mechanism of KD and its role in managing epilepsy and its associated comorbidities.
doi_str_mv 10.2174/1570159X20666220420130109
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9886834</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35450526</sourcerecordid><originalsourceid>FETCH-LOGICAL-b550t-649bc09da16fd742e9902af5a3e4ee93e32bbe93c47f1c2ab1195d14bcf626793</originalsourceid><addsrcrecordid>eNp1ks-O1DAMxisEYv_AK6DwAIUkbdrmgoSGXRixIy4gcbPS1J0G2qRK0hmtuPPcpDswggMnW_Hnz45-zrKXjL7irC5fM1FTJuRXTquq4pyWnLKCMiofZZesqUVeMUkfpzzp8lV4kV2F8I1SLhpeP80uClEKKnh1mf3Y2mD2QwzE2OhIHJBscByXUXmytRG90tE4G4iyHdm5EfVDaYd6UNaEKRDXk48Y3R6t0eSdwUh658nGTbPHAZP7AclOWbXHCW1c5TezGXEO98-yJ70aAz7_Ha-zL7c3nzcf8rtP77ebt3d5KwSNeVXKVlPZKVb1XV1ylJJy1QtVYIkoCyx426aoy7pnmquWMSk6Vra6r3hVy-I6e3PynZd2wk6nNbwaYfZmUv4enDLwb8WaAfbuALJpqqYok4E8GWjvQvDYn3sZhZUI_JdI6n3x9_Bz5x8ESfDzJGjT9EFNQRu0Gs_CIcYZjscj4OLxuwqYGETQbgI3o138mPIEykaYhxkSBo-gfDR6RDAhWFgvAtaLgIMblwmB07WwIDAGYU5g0kv65S8kwL6G</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Insights into the Cellular Interactions and Molecular Mechanisms of Ketogenic Diet for Comprehensive Management of Epilepsy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kumar, Amit ; Kumari, Savita ; Singh, Damanpreet</creator><creatorcontrib>Kumar, Amit ; Kumari, Savita ; Singh, Damanpreet</creatorcontrib><description>A high-fat diet with appropriate protein and low carbohydrate content, widely known as the ketogenic diet (KD), is considered as an effective non-pharmacotherapeutic treatment option for certain types of epilepsies. Several preclinical and clinical studies have been carried out to elucidate its mechanism of antiepileptic action. Ketone bodies produced after KD's breakdown interact with cellular excito-inhibitory processes and inhibit abnormal neuronal firing. The generated ketone bodies decrease glutamate release by inhibiting the vesicular glutamate transporter 1 and alter the transmembrane potential by hyperpolarization. Apart from their effect on the well-known pathogenic mechanisms of epilepsy, some recent studies have shown the interaction of KD metabolites with novel neuronal targets, particularly adenosine receptors, adenosine triphosphate-sensitive potassium channel, mammalian target of rapamycin, histone deacetylase, hydroxycarboxylic acid receptors, and the NLR family pyrin domain containing 3 inflammasomes to suppress seizures. The role of KD in augmenting gut microbiota as a potential mechanism for epileptic seizure suppression has been established. Furthermore, some recent findings also support the beneficial effect of KD against epilepsy- associated comorbidities. Despite several advantages of the KD in epilepsy management, its use is also associated with a wide range of side effects. Hypoglycemia, excessive ketosis, acidosis, renal stones, cardiomyopathies, and other metabolic disturbances are the primary adverse effects observed with the use of KD. However, in some recent studies, modified KD has been tested with lesser side effects and better tolerability. The present review discusses the molecular mechanism of KD and its role in managing epilepsy and its associated comorbidities.</description><identifier>ISSN: 1570-159X</identifier><identifier>EISSN: 1875-6190</identifier><identifier>DOI: 10.2174/1570159X20666220420130109</identifier><identifier>PMID: 35450526</identifier><language>eng</language><publisher>United Arab Emirates: Bentham Science Publishers Ltd</publisher><subject>Anticonvulsants ; Diet, Ketogenic ; Epilepsy - metabolism ; Humans ; Ketone Bodies - metabolism ; Neurology ; Seizures</subject><ispartof>Current neuropharmacology, 2022-01, Vol.20 (11), p.2034-2049</ispartof><rights>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</rights><rights>2022 Bentham Science Publishers 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b550t-649bc09da16fd742e9902af5a3e4ee93e32bbe93c47f1c2ab1195d14bcf626793</citedby><cites>FETCH-LOGICAL-b550t-649bc09da16fd742e9902af5a3e4ee93e32bbe93c47f1c2ab1195d14bcf626793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886834/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886834/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35450526$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumar, Amit</creatorcontrib><creatorcontrib>Kumari, Savita</creatorcontrib><creatorcontrib>Singh, Damanpreet</creatorcontrib><title>Insights into the Cellular Interactions and Molecular Mechanisms of Ketogenic Diet for Comprehensive Management of Epilepsy</title><title>Current neuropharmacology</title><addtitle>CN</addtitle><description>A high-fat diet with appropriate protein and low carbohydrate content, widely known as the ketogenic diet (KD), is considered as an effective non-pharmacotherapeutic treatment option for certain types of epilepsies. Several preclinical and clinical studies have been carried out to elucidate its mechanism of antiepileptic action. Ketone bodies produced after KD's breakdown interact with cellular excito-inhibitory processes and inhibit abnormal neuronal firing. The generated ketone bodies decrease glutamate release by inhibiting the vesicular glutamate transporter 1 and alter the transmembrane potential by hyperpolarization. Apart from their effect on the well-known pathogenic mechanisms of epilepsy, some recent studies have shown the interaction of KD metabolites with novel neuronal targets, particularly adenosine receptors, adenosine triphosphate-sensitive potassium channel, mammalian target of rapamycin, histone deacetylase, hydroxycarboxylic acid receptors, and the NLR family pyrin domain containing 3 inflammasomes to suppress seizures. The role of KD in augmenting gut microbiota as a potential mechanism for epileptic seizure suppression has been established. Furthermore, some recent findings also support the beneficial effect of KD against epilepsy- associated comorbidities. Despite several advantages of the KD in epilepsy management, its use is also associated with a wide range of side effects. Hypoglycemia, excessive ketosis, acidosis, renal stones, cardiomyopathies, and other metabolic disturbances are the primary adverse effects observed with the use of KD. However, in some recent studies, modified KD has been tested with lesser side effects and better tolerability. The present review discusses the molecular mechanism of KD and its role in managing epilepsy and its associated comorbidities.</description><subject>Anticonvulsants</subject><subject>Diet, Ketogenic</subject><subject>Epilepsy - metabolism</subject><subject>Humans</subject><subject>Ketone Bodies - metabolism</subject><subject>Neurology</subject><subject>Seizures</subject><issn>1570-159X</issn><issn>1875-6190</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1ks-O1DAMxisEYv_AK6DwAIUkbdrmgoSGXRixIy4gcbPS1J0G2qRK0hmtuPPcpDswggMnW_Hnz45-zrKXjL7irC5fM1FTJuRXTquq4pyWnLKCMiofZZesqUVeMUkfpzzp8lV4kV2F8I1SLhpeP80uClEKKnh1mf3Y2mD2QwzE2OhIHJBscByXUXmytRG90tE4G4iyHdm5EfVDaYd6UNaEKRDXk48Y3R6t0eSdwUh658nGTbPHAZP7AclOWbXHCW1c5TezGXEO98-yJ70aAz7_Ha-zL7c3nzcf8rtP77ebt3d5KwSNeVXKVlPZKVb1XV1ylJJy1QtVYIkoCyx426aoy7pnmquWMSk6Vra6r3hVy-I6e3PynZd2wk6nNbwaYfZmUv4enDLwb8WaAfbuALJpqqYok4E8GWjvQvDYn3sZhZUI_JdI6n3x9_Bz5x8ESfDzJGjT9EFNQRu0Gs_CIcYZjscj4OLxuwqYGETQbgI3o138mPIEykaYhxkSBo-gfDR6RDAhWFgvAtaLgIMblwmB07WwIDAGYU5g0kv65S8kwL6G</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Kumar, Amit</creator><creator>Kumari, Savita</creator><creator>Singh, Damanpreet</creator><general>Bentham Science Publishers Ltd</general><general>Bentham Science Publishers</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20220101</creationdate><title>Insights into the Cellular Interactions and Molecular Mechanisms of Ketogenic Diet for Comprehensive Management of Epilepsy</title><author>Kumar, Amit ; Kumari, Savita ; Singh, Damanpreet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b550t-649bc09da16fd742e9902af5a3e4ee93e32bbe93c47f1c2ab1195d14bcf626793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anticonvulsants</topic><topic>Diet, Ketogenic</topic><topic>Epilepsy - metabolism</topic><topic>Humans</topic><topic>Ketone Bodies - metabolism</topic><topic>Neurology</topic><topic>Seizures</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumar, Amit</creatorcontrib><creatorcontrib>Kumari, Savita</creatorcontrib><creatorcontrib>Singh, Damanpreet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumar, Amit</au><au>Kumari, Savita</au><au>Singh, Damanpreet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insights into the Cellular Interactions and Molecular Mechanisms of Ketogenic Diet for Comprehensive Management of Epilepsy</atitle><jtitle>Current neuropharmacology</jtitle><addtitle>CN</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>20</volume><issue>11</issue><spage>2034</spage><epage>2049</epage><pages>2034-2049</pages><issn>1570-159X</issn><eissn>1875-6190</eissn><abstract>A high-fat diet with appropriate protein and low carbohydrate content, widely known as the ketogenic diet (KD), is considered as an effective non-pharmacotherapeutic treatment option for certain types of epilepsies. Several preclinical and clinical studies have been carried out to elucidate its mechanism of antiepileptic action. Ketone bodies produced after KD's breakdown interact with cellular excito-inhibitory processes and inhibit abnormal neuronal firing. The generated ketone bodies decrease glutamate release by inhibiting the vesicular glutamate transporter 1 and alter the transmembrane potential by hyperpolarization. Apart from their effect on the well-known pathogenic mechanisms of epilepsy, some recent studies have shown the interaction of KD metabolites with novel neuronal targets, particularly adenosine receptors, adenosine triphosphate-sensitive potassium channel, mammalian target of rapamycin, histone deacetylase, hydroxycarboxylic acid receptors, and the NLR family pyrin domain containing 3 inflammasomes to suppress seizures. The role of KD in augmenting gut microbiota as a potential mechanism for epileptic seizure suppression has been established. Furthermore, some recent findings also support the beneficial effect of KD against epilepsy- associated comorbidities. Despite several advantages of the KD in epilepsy management, its use is also associated with a wide range of side effects. Hypoglycemia, excessive ketosis, acidosis, renal stones, cardiomyopathies, and other metabolic disturbances are the primary adverse effects observed with the use of KD. However, in some recent studies, modified KD has been tested with lesser side effects and better tolerability. The present review discusses the molecular mechanism of KD and its role in managing epilepsy and its associated comorbidities.</abstract><cop>United Arab Emirates</cop><pub>Bentham Science Publishers Ltd</pub><pmid>35450526</pmid><doi>10.2174/1570159X20666220420130109</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1570-159X
ispartof Current neuropharmacology, 2022-01, Vol.20 (11), p.2034-2049
issn 1570-159X
1875-6190
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9886834
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Anticonvulsants
Diet, Ketogenic
Epilepsy - metabolism
Humans
Ketone Bodies - metabolism
Neurology
Seizures
title Insights into the Cellular Interactions and Molecular Mechanisms of Ketogenic Diet for Comprehensive Management of Epilepsy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T12%3A10%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insights%20into%20the%20Cellular%20Interactions%20and%20Molecular%20Mechanisms%20of%20Ketogenic%20Diet%20for%20Comprehensive%20Management%20of%20Epilepsy&rft.jtitle=Current%20neuropharmacology&rft.au=Kumar,%20Amit&rft.date=2022-01-01&rft.volume=20&rft.issue=11&rft.spage=2034&rft.epage=2049&rft.pages=2034-2049&rft.issn=1570-159X&rft.eissn=1875-6190&rft_id=info:doi/10.2174/1570159X20666220420130109&rft_dat=%3Cpubmed_cross%3E35450526%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35450526&rfr_iscdi=true